Maternal pregravid weight is the primary determinant of serum leptin and its metabolic associations in pregnancy, irrespective of gestational glucose tolerance status by Maple-Brown, Louise J. et al.
Maternal Pregravid Weight Is the Primary
Determinant of Serum Leptin and Its Metabolic
Associations in Pregnancy, Irrespective of Gestational
Glucose Tolerance Status
L. Maple-Brown, C. Ye, A. J. Hanley, P. W. Connelly, M. Sermer, B. Zinman,
and R. Retnakaran
Leadership Sinai Centre for Diabetes (L.M.-B., C.Y., A.J.H., P.W.C., B.Z., R.R.), Division of Obstetrics and
Gynecology (M.S.), and Samuel Lunenfeld Research Institute (B.Z.), Mount Sinai Hospital, Toronto,
Canada M5T 3L9; Menzies School of Health Research (L.M.-B.), Charles Darwin University, and Division
of Medicine (L.M.-B.), Royal Darwin Hospital, Darwin NT 0811, Australia; Department of Nutritional
Sciences and Dalla Lana School of Public Health (A.J.H.), Division of Endocrinology (A.J.H., B.Z., R.R.),
and Department of Laboratory Medicine and Pathobiology (P.W.C.), University of Toronto, Toronto,
Canada M5S 1A1; and Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s
Hospital (P.W.C.), Toronto, Canada M5B 1W8
Context: Several previous studies have investigated circulating levels of the adipokine leptin in
relation to gestational diabetes mellitus (GDM). However, these studies have yielded markedly
conflicting results, including increased, decreased, and unchanged leptin levels in women with
GDM as compared with their peers.
Objective: We sought to evaluate the metabolic determinants of serum leptin in a well-charac-
terized cohort reflecting the full spectrum of glucose intolerance in pregnancy.
Design, Setting, andParticipants:Metabolic characterization, includingoral glucose tolerance test
(OGTT) andmeasurement of serum leptin, insulin, lipids, adiponectin, and C-reactive protein, was
performed in 817 pregnant women. The OGTT identified 198 women with GDM, 142 with gesta-
tional impaired glucose tolerance, and 477 with normal glucose tolerance.
Results: Median leptin (ng/ml) did not differ between the normal glucose tolerance (33.7), ges-
tational impaired glucose tolerance (36.3), and GDM (36.4) groups (P  0.085). On univariate
correlation analysis, leptinwasmost strongly associatedwith prepregnancy bodymass index (BMI)
(r  0.54, P  0.0001), fasting insulin (r  0.60, P  0.0001), and C-reactive protein (r  0.38, P 
0.0001) but onlyweakly associatedwith area under theglucose curve (AUCglucose) on theOGTT (r
0.10, P  0.0066). On multiple linear regression analysis, the strongest independent determinant
of leptin was prepregnancy BMI (t  11.55, P  0.0001), whereas AUCglucose was not a significant
predictor (t  0.95, P  0.34). Furthermore, although its respective associations with fasting
insulin, triglycerides, and adiponectin varied across tertiles of prepregnancy BMI, leptin was not
significantly associated with AUCglucose in any BMI tertile.
Conclusions: Pregravid BMI, rather than gestational glucose tolerance, is the primary determinant
of serum leptin concentration in pregnancy. (J Clin Endocrinol Metab 97: 4148–4155, 2012)
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Leptin is an adipocyte-secreted hormone (adipokine)with pleiotropic bioactivity, including effects on reg-
ulation of body weight, energy homeostasis, reproduc-
tion, and immune function (1, 2). Although it has been
proposed as a biomarker of diabetic risk, studies of leptin
as a predictor of type 2 diabetes have yielded variable
results (3–8). The relationship between leptin and gesta-
tional diabetes mellitus (GDM) remains similarly unclear
because, although several previous studies have investi-
gated leptin levels in GDM, they have yielded markedly
conflicting results. Indeed, whereas many studies have re-
ported antepartum leptin levels to be higher in women
with GDM than in their peers (9–15), others have found
no difference (16–18). Moreover, some studies have even
reported lower leptin concentrations in women with
GDM compared with their peers (19, 20). Importantly, it
should be noted that these studies have been limited by 1)
modest numbersofwomenwithGDM,2)heterogeneity in
the glucose tolerance status of comparators, and 3) vary-
ingdegreesof adjustment forpotential confounders.Thus,
hypothesizing that these limitations have contributed to
this inconclusive literature, our objective was to evaluate
the metabolic determinants of serum leptin in a large co-
hort of women reflecting the full spectrum of glucose in-
tolerance in pregnancy, with adjustment for a broad array
of potential covariates.
Subjects and Methods
Study population
This analysis was conducted as part of an ongoing cohort
study in which pregnant women are recruited at the time of
antepartum screening for GDM (21). The study protocol was
approved by the Mount Sinai Hospital Research Ethics Board
and has been described in detail previously (21, 22). In brief, all
participants undergo a 3-h 100-g oral glucose tolerance test
(OGTT) in late second/early third trimester and simultaneous
metabolic characterization consisting of interviewer-adminis-
tered questionnaires, physical examination, and assessment of
cardiometabolic risk factors.Aspreviously described, theOGTT
enables stratification of participants into the following three ges-
tational glucose tolerance categories: 1) GDM (defined by ex-
ceedingat least twoglycemic thresholdson theOGTT,asdefined
by National Diabetes Data Group criteria); 2) gestational im-
paired glucose tolerance (GIGT, defined by exceeding one Na-
tional Diabetes Data Group glycemic threshold); or 3) normal
glucose tolerance (NGT). All participants provided written in-
formed consent. The current analysis was restricted to women
with singleton pregnancies (n  817).
Laboratory measurements
All OGTT were performed in the morning after an overnight
fast.During theOGTT,venousbloodsamplesweredrawnformea-
surement of glucose and insulin at fasting and at 30, 60, 120, and
180 min after ingestion of the glucose load. The area under the
glucose-curve during the OGTT (AUCglucose) was calculated by
trapezoidal rule, thereby providing a continuous measure of glyce-
mia to complement the categorical glucose tolerance status defined
TABLE 1. Participant characteristics by glucose tolerance status in pregnancy
Characteristic
NGT
(n  477)
GIGT
(n  142)
GDM
(n  198) P value
Age (yr) 34.0  4.2 33.9  4.3 34.6  4.5 0.1796
Weeks gestation at OGTT 30  2.9 30  3.0 29  2.9 0.0144
Ethnicity
White (%) 350 (73.4) 96 (67.6) 123 (62.1) 0.0217
Asian (%) 48 (10.1) 23 (16.2) 35 (17.7)
Other (%) 79 (16.6) 23 (16.2) 40 (20.2)
Family history of DM 251 (52.6) 84 (59.2) 136 (68.7) 0.0006
Parity
Nulliparous 255 (53.5) 80 (56.3) 110 (55.6) 0.7825
1 222 (46.6) 62 (43.7) 88 (44.4)
Previous GDMa 18 (3.8) 14 (9.9) 17 (8.6) 0.0058
Prepregnancy BMI (kg/m2) 23.2 (21.1–26.5) 23.2 (21.3–26.6) 24.6 (22.1–28.9) 0.0002
Gestational weight gain up to OGTT (kg) 11.1  5.4 11.0  5.0 10.1  5.3 0.0799
AUCglucose on OGTT 20.6  2.4 24.7  2.5 28.0  2.5 0.0001
Fasting insulin (pmol/liter) 57 (40–79) 71.5 (52–99) 79 (48–115) 0.0001
LDL cholesterol (mmol/liter) 3.7  1.1 3.6  1.2 3.5  1.2 0.1637
HDL cholesterol (mmol/liter) 1.7  0.4 1.7  0.3 1.6  0.4 0.0001
Triglycerides (mmol/liter) 2.4  0.8 2.5  0.9 2.7  0.8 0.0002
CRP (mg/liter) 4.1 (2.4–7.0) 4.0 (2.0–7.5) 5.6 (3.2–9.6) 0.0001
Adiponectin (g/ml) 8.4  3.0 7.4  2.6 7.0  2.4 0.0001
Leptin (ng/ml) 33.7 (23.1–48.6) 36.3 (23.6–48.1) 36.4 (26.2–50.5) 0.0852
Continuous data are presented as mean  SD, with the exception of the skewed variables prepregnancy BMI, fasting insulin, CRP, and leptin
(which are presented as median followed by interquartile range in parentheses). Categorical data are presented as n (percent). P values refer to
overall differences across groups using analysis of variance for continuous variables or 2 test for categorical variables.
a Previous GDM or delivery of a macrosomic infant.
J Clin Endocrinol Metab, November 2012, 97(11):4148–4155 jcem.endojournals.org 4149
above. Specific insulin was measured using the Roche Modular
systemand the electrochemiluminescence immunoassaykit (Roche
Diagnostics, Laval, Quebec, Canada). Fasting lipids (total choles-
terol,high-density lipoprotein (HDL)cholesterol, andtriglycerides)
weremeasuredusing theRocheCobas 6000 c 501 analyzer (Roche
Diagnostics),with low-density lipoprotein (LDL) cholesterol deter-
mined by Friedewald formula. Fasting serum leptin was measured
by ELISA EZHL-80SK (Millipore, Linco Research, St. Charles,
MO). Total adiponectinwasmeasured byELISA (Millipore, Linco
Research).High-sensitivityC-reactiveprotein (CRP)wasmeasured
by endpoint nephelometryusing theDade-BehringBNProspec and
the N high-sensitivity CRP reagent (Dade-Behring, Mississauga,
Ontario, Canada).
Statistical analyses
All analyses were conducted using SAS version 9.2 (SAS In-
stitute,Cary,NC). InTable 1, data are presented asmean (SD) for
normally distributed continuous variables and as median (inter-
quartile range) for skewed variables. Natural log transforma-
tions were used in subsequent analyses of skewed variables,
where necessary. The 2 tests (categorical variables) and
ANOVA (continuous variables) were used to determine differ-
ences across the three glucose tolerance categories in pregnancy.
Univariate correlations between leptin and continuous variables
were assessed by Spearman correlation analysis (Table 2). Mul-
tiple linear regression analysis was performed to determine in-
dependent relationships between antepartumcharacteristics and
dependent variable leptin (Table 3). Covariates included in this
analysis consisted of demographic/clinical variables (age, eth-
nicity, and family history of diabetes), reproductive factors (par-
ity, previous GDM, and weeks gestation at OGTT), and meta-
bolic factors [prepregnancy BMI, gestational weight gain up to
theOGTT,AUCglucose, fasting insulin, LDL,HDL, triglycerides,
CRP, and adiponectin]. Owing to the significant interactions of
metabolic variables (AUCglucose, fasting insulin, and adiponec-
tin) with prepregnancy BMI, the multiple linear regression anal-
yses were repeated after stratification of the study population
into tertiles of pregravid BMI (Table 4).
Results
Table 1 shows the characteristics of the study population
stratified into the following three gestational glucose toler-
ance groups: NGT (n 477), GIGT (n 142), and GDM
(n198). Therewere no significant differences between the
groups in age or parity. The antepartum OGTT was per-
formed slightly earlier inwomenwithGDM (median 29wk
compared with 30 wk in the other two groups; overall P
0.014). As expected, there were significant differences be-
tweenthethreeglucose tolerancegroups inGDMriskfactors
(ethnicity, family history of diabetes, previous GDM,
prepregnancy BMI) and metabolic variables (AUCglucose,
fasting insulin,HDLcholesterol, triglycerides,CRP,andadi-
ponectin). However, there was no significant difference in
leptin concentration across the gestational glucose tolerance
groups (P 0.085).
On Spearman univariate correlation analysis (Table 2),
leptin was most strongly associated with prepregnancy
BMI (r 0.54, P 0.0001), fasting insulin (r 0.60, P
0.0001), CRP (r  0.38, P  0.0001), adiponectin (r 
0.24,P 0.0001), and gestational weight gain up to the
OGTT (r 0.15, P 0.0001). However, leptin was only
weakly associatedwithAUCglucose (r0.10,P0.0066).
Weak inverse associations with LDL (r  0.09, P 
0.0088) and age (r0.07, P 0.042) were also noted.
On multiple linear regression analysis (Table 3), a
model consisting of age, weeks gestation, ethnicity, family
history of diabetes, parity, previous GDM, prepregnancy
BMI, gestational weight gain, AUCglucose, fasting insulin,
LDL,HDL, triglycerides,CRP, andadiponectin explained
51.4%of the variance associatedwith dependent variable
leptin. This analysis revealed that the strongest indepen-
TABLE 2. Spearman correlations of maternal metabolic
variables with leptin
Variable
Correlation
coefficient
P
value
Age 0.07 0.0423
Weeks gestation 0.04 0.2991
Prepregnancy BMI 0.54 0.0001
Gestational weight gain up to OGTT 0.15 0.0001
AUCglucose 0.10 0.0066
Fasting insulin 0.60 0.0001
LDL cholesterol 0.09 0.0088
HDL cholesterol 0.04 0.2540
Triglycerides 0.04 0.2945
CRP 0.38 0.0001
Adiponectin 0.24 0.0001
TABLE 3. Multiple linear regression analysis of
(dependent variable) leptin (model adjusted
R2  51.4%)
Variable
-
coefficient SE t P
Age 0.0010 0.0038 0.26 0.7938
Weeks gestation 0.0056 0.0059 0.96 0.3384
Ethnicity
Asian 0.0269 0.0532 0.50 0.6140
Other 0.1493 0.0436 3.43 0.0006
Family history DM 0.0012 0.0317 0.04 0.9706
Parity 1 0.1635 0.0328 4.98 0.0001
Previous GDMa 0.0472 0.0691 0.68 0.4949
Prepregnancy BMI 0.0466 0.0040 11.55 0.0001
Gestational weight
gain up to OGTT
0.0308 0.0033 9.30 0.0001
AUCglucose 0.0040 0.0042 0.95 0.3416
Fasting insulinb 0.3566 0.0358 9.97 0.0001
LDL cholesterol 0.0186 0.0143 1.26 0.2073
HDL cholesterol 0.0720 0.0471 1.53 0.1264
Triglycerides 0.0694 0.0259 2.68 0.0076
CRPb 0.1256 0.01937 6.48 0.0001
Adiponectin 0.0023 0.0065 0.36 0.7217
Reference group for ethnicity is Caucasian.
a Previous GDM or macrosomic infant.
b Log transformed.
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dent determinant of leptin was prepregnancy BMI (t 
11.55,P0.0001).Other significant covariateswere fast-
ing insulin (t 9.97, P 0.0001), gestational weight gain
up to the OGTT (t  9.30, P  0.0001), CRP (t  6.48,
P  0.0001), parity of at least one (t  4.98, P 
0.0001), ethnicity other than Caucasian or Asian (t 
3.43, P  0.0006), and triglycerides (t  2.68, P 
0.0076). Repeating thismultiple linear regression analysis
with categorical glucose tolerance status (NGT, GIGT,
and GDM) as a covariate in place of AUCglucose yielded
the very same significant predictors, with neither GDM
(t1.23, P 0.22) nor GIGT (t0.81, P 0.42)
emerging as independent covariates of leptin (data not
shown).
On testing the model in Table 3 for interactions be-
tween covariates, we found significant interactions be-
tween prepregnancy BMI and each of the following vari-
ables: AUCglucose (interaction P 0.0004), fasting insulin
(interaction P  0.0001), and adiponectin (interaction
P  0.0001). In light of these findings, we stratified the
study population into tertiles of prepregnancy BMI and
repeated themultiple linear regressionmodelswithin each
of these three groups (Table 4). These analyses revealed
that prepregnancy BMI, gestational weight gain, fasting
insulin, CRP, and parity were independently associated
with leptin within each BMI tertile. In contrast, the sig-
nificant associations between leptin and ethnicity and trig-
lycerides andadiponectin, respectively,were found inonly
certain tertiles.
Figure 1 shows examples of different patterns of ef-
fect modification by prepregnancy BMI on the meta-
bolic correlates of antepartum leptin. First, as shown in
Fig. 1A, AUCglucose was not significantly associated
with leptin in any BMI tertile, although it may be trend-
ing toward a weak inverse relationship in the heaviest
women (third tertile). In contrast, although fasting in-
sulin was significantly correlated with leptin in all three ter-
tiles (Fig. 1B), the magnitude of this association was far
greater in the leanest women ( 0.53) than in the middle
or heaviest tertiles (  0.33 and   0.21, respectively).
Third, triglyceride level (Fig. 1C) was inversely associ-
ated with leptin in the leanest women (  0.17, P 
0.001) but not at all related in the middle (  0.04,
P  0.35) and highest (  0.06, P  0.19) tertiles.
Lastly, adiponectin (Fig. 1D) was significantly corre-
lated with leptin in only the middle tertile of prepreg-
nancy BMI (  0.03, P  0.035).
As a supplemental analysis, the multiple linear regres-
sion models of leptin were repeated after stratifying the
study population into the following three groups based on
prepregnancy BMI: 1) BMI below 25 kg/m2 (n 512); 2)
BMI between 25.0 and 29.99 kg/m2 inclusive (n  183);
and3)BMI30.0kg/m2orhigher (n122).These analyses
TABLE 4. Multiple linear regression analyses of (dependent variable) leptin within each tertile of prepregnancy BMI
Variable
First BMI tertile
(BMI  16.6–22.0 kg/m2);
model-adjusted
R2  41.3%
Second BMI tertile
(BMI  22.0–25.5 kg/m2);
model-adjusted
R2  39.7%
Third BMI tertile
(BMI  25.5–56.9 kg/m2);
model-adjusted
R2  36.0%
-coefficient
(SE) P
-coefficient
(SE) P
-coefficient
(SE) P
Age 0.0048 (0.0076) 0.5267 0.005 (0.0065) 0.9442 0.0058 (0.0056) 0.3009
Weeks gestation 0.0163 (0.0115) 0.1554 0.0106 (0.0113) 0.3471 0.0074 (0.0080) 0.3543
Ethnicity
Asian 0.0494 (0.0903) 0.5850 0.0484 (0.0924) 0.6007 0.0344 (0.0973) 0.7241
Other 0.1260 (0.0864) 0.1460 0.2325 (0.0763) 0.0026 0.1316 (0.0640) 0.0410
Family history of DM 0.0575 (0.0590) 0.3307 0.0114 (0.0531) 0.8302 0.0440 (0.0509) 0.3882
Parity 1 0.1275 (0.0623) 0.0419 0.1879 (0.0569) 0.0011 0.1194 (0.0505) 0.0189
Previous GDMa 0.0196 (0.1424) 0.8908 0.0581 (0.1194) 0.6271 0.0818 (0.0977) 0.4031
Prepregnancy BMI 0.0863 (0.0264) 0.0012 0.0897 (0.0267) 0.0009 0.0361 (0.0060) <0.0001
Gestational weight gain up to OGTT 0.0386 (0.0075) <0.0001 0.0321 (0.0059) <0.0001 0.0219 (0.0044) <0.0001
AUCglucose 0.0025 (0.0080) 0.7574 0.0001 (0.0074) 0.9884 0.0110 (0.0063) 0.0831
Fasting insulinb 0.5282 (0.0724) <0.0001 0.3319 (0.0596) <0.0001 0.2115 (0.0559) 0.0002
LDL cholesterol 0.0107 (0.0282) 0.7057 0.0105 (0.0247) 0.6715 0.0067 (0.0230) 0.7704
HDL cholesterol 0.0417 (0.0880) 0.6356 0.0900 (0.0824) 0.2755 0.1325 (0.0710) 0.0631
Triglycerides 0.1715 (0.0522) 0.0012 0.0387 (0.0410) 0.3469 0.0552 (0.0419) 0.1897
CRPb 0.1082 (0.0343) 0.0018 0.1470 (0.033) <0.0001 0.1001 (0.0329) 0.0027
Adiponectin 0.0109 (0.0114) 0.3434 0.0250 (0.0118) 0.0347 0.0086 (0.0104) 0.4114
Values in bold indicate P  0.05. Reference group for ethnicity is Caucasian.
a Previous GDM or macrosomic infant.
b Log transformed.
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showed that, as with the tertile analysis in Table 4,
prepregnancy BMI and gestational weight gain up to the
OGTT were positive independent predictors of leptin in
each of the three groups, whereas AUCglucose was not as-
sociated with leptin in any group, and other variables had
group-specific associations that varied according to the
prepregnancy BMI group (Supplemental Table 1, pub-
lishedonTheEndocrineSociety’s JournalsOnlineweb site
at http://jcem.endojournals.org).
Discussion
Previous reports of antepartum serum leptin inGDMhave
been conflicting; several studies have reported higher lep-
tin levels in GDM than in NGT controls (9–13), whereas
others have reported lower leptin levels inGDMthan con-
trols after adjusting or matching for BMI (19, 20), and
finally, other studies have reported no difference in leptin
concentration between participants with and without
FIG. 1. Adjusted relationships between log leptin and AUCglucose (A), log fasting insulin (B), triglycerides (C), and adiponectin (D) within each tertile of
prepregnancy BMI. Each relationship is adjusted for the following covariates: age, weeks gestation, ethnicity, family history of diabetes, parity, previous
GDM, prepregnancy BMI, gestational weight gain up to the OGTT, AUCglucose, fasting insulin, LDL, HDL, triglycerides, CRP, and leptin.
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GDM (16–18), including after adjustment for BMI (23).
However, there are important limitations of this literature
that are likely contributing to these conflicting results.
First, these studies have had relatively modest numbers of
women with GDM (generally between 50 and 60), with
the largest reporting only 63 such patients. Second, the
gestational glucose tolerance status of the comparator
women (i.e. the group against which GDMhas been com-
pared) has varied. Specifically, some studies compared the
levels of leptin in GDM against those in women with con-
firmed NGT, whereas other studies defined the compar-
ator group by the absence of GDM (i.e. which could in-
clude gestational glucose intolerance). Third, the previous
studies have varied in the extent of their adjustment for
covariates, an important issue given the relationships be-
tween leptin and numerous metabolic variables. Thus, in
light of these limitations, our study aimed to reconcile the
previously reported conflictingdata through the following
design features: 1) assessment of more than three times as
many participants with GDM than any of the previous
studies, 2) evaluation across the full range of gestational
glucose tolerance status, and 3) adjustment for a broad
array of metabolic variables.
Bolstered by these strengths in study design, our data
demonstrate that there is no significant independent rela-
tionship between glucose tolerance status in pregnancy
and maternal serum leptin levels. The robustness of this
finding is supported by the fact that the regression models
explained a high proportion of the variance in leptin con-
centration (e.g. model adjusted R2  51.4% in Table 3)
and identified several independent determinants thereof,
but neitherAUCglucose norGDMwasoneof them. Instead,
we found that prepregnancy BMI is the primary determi-
nant of leptin levels in pregnancy. Leptin is produced by
adipocytes, is elevated in obese women, and correlates
with BMI and body fat percentage in the setting of preg-
nancy and GDM (9, 23–25). Although placental produc-
tion likely contributes to the rise in circulating leptin levels
that takes place in pregnancy, it has recently been sug-
gested that the overall impact of this placental contribu-
tion is modest (26). Indeed, consistent with this sugges-
tion, we found that pregravid BMI was a much stronger
determinant of antepartum leptin concentration than was
gestational weight gain and that weeks gestation was not
a significant predictor (Tables 2 and 3). Thus, placental
contribution notwithstanding, the current data emphasize
thedominant roleofprepregnancyBMI indetermining the
absolute levels of serum leptin in late pregnancy.
Furthermore, we have also demonstrated that prepreg-
nancy BMI modifies the associations of leptin with various
metabolic factors. As demonstrated in Fig. 1, the impact of
prepregnancy BMI on the relationships between leptin and
cardiometabolic risk factors is complex and varied. Indeed,
triglycerideswere inversely associatedwith leptin in only the
lowest tertile of pregravid BMI, whereas adiponectin was
positively correlated in only the middle tertile. Conversely,
although the significance of their associations with leptin
did not change between tertiles, both fasting insulin and
AUCglucose exhibited significant interactions with prepreg-
nancy BMI. Specifically, the magnitude of the association
beween leptinandfasting insulindecreasedaspregravidBMI
rose, whereas AUCglucose showed a nonsignificant trend to-
wardan inverse relationshipwith leptin in theheaviest tertile
that was not at all apparent in the other two tertiles. Impor-
tantly, our findings emerge only after BMI stratification and
covariate adjustment in a very large sample size across a
broad range of glucose tolerance in pregnancy. This previ-
ously unrecognized aspect of leptin physiology in pregnancy
couldhavealso contributed to the earlier conflicting findings
in the literature and again underscores the central impor-
tance of prepregnancy BMI.
Other independent covariates in themultiple regression
analysis of maternal leptin in the current study included
ethnicity other than Asian or Caucasian, parity of at least
one, and CRP. Although there was no dominant ethnic
group within the other category, ethnic differences in lep-
tin levels have been previously reported (27). The basis for
the inverse association between parity of at least one and
leptin is not clear but potentially may relate to the phys-
iological effects of leptin on reproductive function (28).
Finally, it has previously been demonstrated that physio-
logical concentrations of serum leptin can stimulate he-
patocyte expression of CRP and that CRP can bind to
leptin (as a serum leptin-interacting protein) (29). In doing
so,CRP can block the binding of leptin to its receptors and
thereby induce target tissue insensitivity to the biological
effects of leptin (i.e. leptin resistance) (29). In this context,
the current study confirms that an independent associa-
tion exists between leptin and CRP in pregnancy and is
consistent across BMI categories.
Although the current study demonstrates thatmaternal
adiposity (rather than glucose intolerance) is the primary
determinant of the circulating leptin concentration in
pregnancy, the physiological implications of this relation-
ship remain to be determined. Interestingly, we and others
have demonstrated that, after adjustment for BMI, ma-
ternal serum leptin is inversely associatedwith infant birth
weight (30, 31). These data raise the possibility that, in
pregnancy, leptin may play a role in attenuating the pro-
macrosomic effects of maternal obesity. Ultimately, more
longitudinal study is needed to evaluate the long-term im-
plications of antepartum leptin on outcomes for both
mother and child. With respect to the effects on the off-
spring, it is of interest that maternal glycemia has recently
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been associated with epigenetic modification of the leptin
gene on the fetal side of the placenta (26). Thus, although
our study demonstrates that gestational dysglycemia does
not affect serum leptin levels in pregnancy, it still may be
relevant to long-term leptin physiology in the offspring.
This study is limited by its observational nature and thus
cannot examine causal relationships between leptin, mater-
nal BMI, and cardiometabolic risk factors. Second, this
cross-sectional analysis cannot provide insight on the rela-
tionships between these variables over the course of preg-
nancy.Third, themechanismsunderlying theapparentmod-
ifying effect of prepregnancy BMI are unclear, although
leptin resistance is a recognized phenomenon in other set-
tings (29, 32). Nevertheless, through its evaluation of the
complex relationships between leptin and an array of met-
abolic factors in a large cohort ofwomenacross the full spec-
trumofglucose tolerance inpregnancy, the current studyhas
provided apotential reconciliationof the existing conflicting
literature on leptin in GDM that should lead to additional
studies.
In conclusion, we have reported thatmaternal antepar-
tum leptin levels do not differ significantly across catego-
ries of gestational glucose tolerance. Instead, prepreg-
nancy BMI is a key driver of maternal leptin levels and
modifies the relationships between leptin and several key
cardiometabolic risk factors. With this understanding,
longitudinal studies are now required to assess the role of
leptin in pregnancy and its implications for long-termmet-
abolic risk of mother and offspring.
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